DK3668519T3 - Anvendelse af ginsenosid m1 til fremstilling af et medikament til behandling af mundkræft - Google Patents

Anvendelse af ginsenosid m1 til fremstilling af et medikament til behandling af mundkræft Download PDF

Info

Publication number
DK3668519T3
DK3668519T3 DK19787619.6T DK19787619T DK3668519T3 DK 3668519 T3 DK3668519 T3 DK 3668519T3 DK 19787619 T DK19787619 T DK 19787619T DK 3668519 T3 DK3668519 T3 DK 3668519T3
Authority
DK
Denmark
Prior art keywords
ginsenoside
medicine
manufacture
treatment
oral cancer
Prior art date
Application number
DK19787619.6T
Other languages
Danish (da)
English (en)
Inventor
Kuo-Feng Hua
Yu-Chieh Lee
Sheau-Long Lee
Original Assignee
Lee Sheau Long
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lee Sheau Long filed Critical Lee Sheau Long
Application granted granted Critical
Publication of DK3668519T3 publication Critical patent/DK3668519T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005Glycosides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DK19787619.6T 2018-04-17 2019-04-17 Anvendelse af ginsenosid m1 til fremstilling af et medikament til behandling af mundkræft DK3668519T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862658732P 2018-04-17 2018-04-17
PCT/CN2019/083058 WO2019201280A1 (en) 2018-04-17 2019-04-17 Use of ginsenoside m1 for manufacturing medicament for treating oral cancer

Publications (1)

Publication Number Publication Date
DK3668519T3 true DK3668519T3 (da) 2021-08-23

Family

ID=68239265

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19787619.6T DK3668519T3 (da) 2018-04-17 2019-04-17 Anvendelse af ginsenosid m1 til fremstilling af et medikament til behandling af mundkræft

Country Status (9)

Country Link
US (1) US11524021B2 (https=)
EP (1) EP3668519B1 (https=)
JP (1) JP7307732B2 (https=)
KR (1) KR102709520B1 (https=)
CN (1) CN111615393B (https=)
DK (1) DK3668519T3 (https=)
ES (1) ES2889404T3 (https=)
TW (1) TWI820118B (https=)
WO (1) WO2019201280A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4153072A4 (en) * 2020-05-18 2024-05-22 ChemImage Corporation Systems and methods for detecting oral cancer using molecular chemical imaging
CN115300624A (zh) * 2022-07-08 2022-11-08 中国医学科学院药用植物研究所 人参皂苷联合pd-1阻断剂在制备抗头颈鳞癌药物中的应用
KR20250057225A (ko) 2023-10-19 2025-04-29 단국대학교 천안캠퍼스 산학협력단 차가버섯 추출물을 포함하는 구강암 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59181217A (ja) * 1983-03-30 1984-10-15 Rooto Seiyaku Kk ダンマラン系化合物を含有する抗癌剤組成物
US20030185910A1 (en) * 2002-02-08 2003-10-02 Taik Koo Yun Cancer preventive composition comprising ginsenoside glycosides of red ginseng
WO2005034963A1 (en) * 2003-10-15 2005-04-21 Panagin Pharmaceuticals Inc. USE OF GINSENOSIDES Rh2 & Rg3, AND AGLYCON GINSENOSIDES FOR THE PREVENTION OF CANCER
CN103694297A (zh) * 2013-11-19 2014-04-02 大连杰信生物科技有限公司 提高人参皂苷m1与癸酰氯单酯化选择性的合成方法
EP3137089B1 (en) * 2014-05-02 2018-10-10 Sheau-Long Lee Use of ginsenoside m1 for treating lupus nephritis
EP3270929B1 (en) * 2015-03-17 2019-09-11 Lee, Sheau-Long Use of ginsenoside m1 for preventing or treating silicosis
KR101722547B1 (ko) * 2015-05-22 2017-04-04 한국과학기술원 파낙사디올류 진세노사이드 화합물을 포함하는 항암보조제
CN106236761A (zh) * 2016-07-27 2016-12-21 陕西巨子生物技术有限公司 一种包含稀有人参皂苷c‑k的稀有人参皂苷组合物

Also Published As

Publication number Publication date
KR102709520B1 (ko) 2024-09-25
ES2889404T3 (es) 2022-01-12
US20210023104A1 (en) 2021-01-28
US11524021B2 (en) 2022-12-13
CN111615393A (zh) 2020-09-01
WO2019201280A1 (en) 2019-10-24
JP7307732B2 (ja) 2023-07-12
EP3668519A4 (en) 2020-10-14
TW202002987A (zh) 2020-01-16
TWI820118B (zh) 2023-11-01
KR20200143668A (ko) 2020-12-24
EP3668519B1 (en) 2021-06-16
CN111615393B (zh) 2023-10-10
JP2021517886A (ja) 2021-07-29
EP3668519A1 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
DK3431105T3 (da) Medicinsk sammensætning til behandling af cancer
HUE061874T2 (hu) Anti-PD-1 antitestek és besugárzás kombinált alkalmazása a rák kezelésére
IL286048A (en) Abiraterone prodrugs
EP3597258A4 (en) CATHETER ARRANGEMENT
EP3820549A4 (en) SYRINGE ARRANGEMENT
EP3581183A4 (en) PHARMACEUTICAL COMPOSITION FOR ONCOTHERAPY
EP3565502A4 (en) Oral irrigator
EP4041122C0 (en) WATER INTERDENTAL CLEANER
IL281244A (en) Combination therapy for the treatment of liver disease
EP3746155A4 (en) SYRINGE ARRANGEMENT
EP4073701A4 (en) Integrated dose counter
DK3326637T3 (da) Anvendelse af mangostanskalekstrakt til fremstilling af en medicin til behandling af hudlidelser
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer
EP3784214C0 (en) ORAL LIQUID PHARMACEUTICAL DOSAGE FORM
EP3873444A4 (en) Therapeutic compounds and compositions
EP3868371A4 (en) Novel pharmaceutical composition
IL282157A (en) Compounds and therapeutic uses thereof
DK3668519T3 (da) Anvendelse af ginsenosid m1 til fremstilling af et medikament til behandling af mundkræft
EP3746080A4 (en) PHARMACEUTICAL FORMULATIONS
DK3403674T3 (da) Farmaceutiske sammensætninger til behandling af smerte
EP3927328A4 (en) INHALABLE THERAPEUTIC AGENT
DE112020002320A5 (de) Schmerzmedikament
ZA201907286B (en) A pharmaceutical combination for the treatment of a cancer
EP3700459C0 (fr) Ensemble d'implantation dentaire endo-osseux
IL281782A (en) Drug combination for cancer treatment